This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

DUODOPA (levodopa/carbidopa intestinal gel)

DUODOPA
(levodopa/carbidopa intestinal gel)

PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)

PRODUODOPA
(foslevodopa/foscarbidopa solution for infusion)

A look at Complex/Advanced Parkinson's disease

DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.¹

PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.²

Levodopa may activate malignant melanoma, so PRODUODOPA and DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.^1,2

Some patients may not be suitable for DUODOPA or PRODUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability.

Consider assessing earlier?

Peer-reviewed opinions support earlier introduction of non-oral therapies in patients with Complex/Advanced Parkinson’s disease³

When left too late, non-oral therapies may no longer be an appropriate treatment option for patients with PD³

When initiation of non-oral therapies is left too late, progressive neurodegeneration in PD can mean patients’ capacity to respond to these treatments may be significantly reduced.^3,4

In patients with PD, consider non-oral therapies before severe motor symptoms and loss of functioning worsen.⁵

Based on a peer-reviewed opinion article that aimed to support the social and economic benefits of optimised treatment for patients with PD

Early introduction of non-oral therapies may allow patients with PD to have better control of motor symptoms and an impact on quality of life, which may allow patients to live at home or stay at work for longer⁶

View Study Information

Hospital Episode Statistics (HES) data (2013–2018)^7*

Patients with Complex/Advanced PD treated with non-oral therapies

compared to

Patients with Complex/Advanced PD without dementia and not receiving non-oral therapies

3.6

fewer mean emergency admissions over 5 years^†

45.9 ^%

fewer patients with emergency admissions

53.2

fewer mean 5-year bed days^†

6.7 ^%

fewer patients with record of hip fracture^‡

Patients with Complex/Advanced PD treated with non-oral therapies

compared to

Patients with Complex/Advanced PD without dementia and not receiving non-oral therapies

3.6

fewer mean emergency admissions over 5 years^†

45.9^%

fewer patients with emergency admissions

53.2

fewer mean 5-year bed days^†

6.7^%

fewer patients with record of hip fracture^‡

Patients with Complex/Advanced PD treated with non-oral therapies had fewer emergency hospital admissions and hip fractures compared to those on other treatment^7*†‡

^*Hospital Episode Statistics (HES) is a database of administrative healthcare data maintained by NHS digital. This applies to England only. ^†Means are total admissions over 5 years divided by no. of patients. ^‡Any diagnosis of fracture of femur (ICD-10 Code S72).⁷

HES data for Complex/Advanced PD patients⁷

Parkinson’s UK estimated the prevalence of PD in England at 114,560 in 2015^*†7

Measure All units are N unless specified	All advanced PD patients^‡	Advanced PD patients^‡ without dementia and no advanced treatment	Advanced treatment patients^§
Patients	13,310	7,106	2,499
Males (%)	62.3	59.2	67.7
Mean age (years)^¶	74.2	77.2	61.9
Mean 5-year admissions**	7.4	7.2	6.7
Mean 5-year emergency admissions**	4.9	5.3	1.7
Patients with emergency admission (%)	90.2	98.4	52.5
Mean 5-year bed days**	72.3	75.7	22.5
Patients with overnight stay (%)	97.3	98.7	89.3
Patients with any record of dementia (%)^††	29.8	0.0	10.3
Patients with any record of hip fracture (%)^‡‡	8.7	9.3	2.6

^*PD patients: patients with any diagnosis of PD, primary or secondary (ICD-10 code G20, PD). ^†Estimated value using age and gender-specific prevalence rates from the Clinical Practice Research Datalink (CPRD) and extrapolated to the population of England in mid-2015 to estimate the number of people living with Parkinson’s. The study population consisted of patients aged 20 or over with a record for Parkinson’s in their clinical or referral file during the period 1 January 1988 to 31 December 2015. Patients with <6 months of up-to-standard follow-up in the CPRD were also excluded. ^‡Advanced PD patients: patients with a primary diagnosis of PD AND any diagnosis of abnormalities of gait and mobility (ICD-10 code R26, abnormalities of gait and mobility) OR any diagnosis of dyskinesia (ICD-10 codes G248/249, G248 (other dystonia) and G249 (dystonia unspecified) record dyskinesia where it is not specified in G240–247). ^§Advanced treatment patients: patients with a record of deep brain stimulation, apomorphine or Duodopa (levodopa/carbidopa intestinal gel). ^¶Age at first admission with any Parkinson’s disease diagnosis. ^**Means are total admissions over 5 years divided by number of patients. ^††Any diagnosis of either Dementia in Parkinson’s disease (ICD-10 Code F023) or Hallucinations (R44) or Persistent delusional disorders (F22). ^‡‡Any diagnosis of Fracture of Femur (ICD-10 Code S72).

Discover more about the ‘5 or 2 or 1’ criteria

Learn more

Stay connected

Keep up to date with future resources, support, and guidance to help you manage your patients with PD by filling out your details below and joining the mailing list.

Please only fill out your details if you are a UK registered healthcare professional.

First name:*

Please enter First name

Last name:*

Please enter Last name

E-mail address:*

E-mail address is not valid

Hospital name:

Please enter Hospital name

I consent to receive AbbVie Ltd communications

I consent to receive AbbVie Ltd communications about its products, services, research, events, programmes and other information, including promotional content, that may be of interest to me, using the information I provide. I may withdraw my consent at any time.

Please select one field.

Please refer to the AbbVie privacy notice for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

1. DUODOPA (levodopa/carbidopa intestinal gel) SmPC.

2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) SmPC.

3. Mills J, Martin A. Br J Neurosci Nurs. 2015; 11(2): 92–7.

4. Thanvi BR, Lo TCN. Postgrad Med J. 2004; 80(946): 452–8.

5. Worth PF. Pract Neurol 2013; 13: 140–52.

6. Lökk J, et al. Eur Neurol Rev. 2012; 7(2): 113–7.

7. AbbVie Ltd. Data on File. REF-37728.

DUODOPA PRESCRIBING INFORMATION

PRODUODOPA PRESCRIBING INFORMATION

By clicking the links above you will leave the AbbVie Pro website and be taken to the eMC PI portal website

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-PRODD-240196. Date of preparation: December 2024

Lökk J, et al. 2012⁷

Study type: Peer-reviewed opinion article.

Aim: To support the social and economic benefits of optimised treatment for patients with Parkinson’s disease.

Methods: Commentary on the economic burden of Parkinson’s disease (PD) citing 10 publications concerning health economic data and modelling, including an economic simulation study that compared the costs of standard of care vs. duodopa^®(levodopa/carbidopa intestinal gel).

A look at Complex/Advanced Parkinson's disease

Consider assessing earlier?

Peer-reviewed opinions support earlier introduction of non-oral therapies in patients with Complex/Advanced Parkinson’s disease³

When left too late, non-oral therapies may no longer be an appropriate treatment option for patients with PD³

Hospital Episode Statistics (HES) data (2013–2018)^7*

compared to

3.6

45.9

^%

53.2

6.7

^%

compared to

3.6

45.9^%

53.2

6.7^%

Patients with Complex/Advanced PD treated with non-oral therapies had fewer emergency hospital admissions and hip fractures compared to those on other treatment^7*†‡

HES data for Complex/Advanced PD patients⁷

Stay connected

Lökk J, et al. 2012⁷

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome

A look at Complex/Advanced Parkinson's disease

Consider assessing earlier?

Peer-reviewed opinions support earlier introduction of non-oral therapies in patients with Complex/Advanced Parkinson’s disease3

When left too late, non-oral therapies may no longer be an appropriate treatment option for patients with PD3

Hospital Episode Statistics (HES) data (2013–2018)7*

compared to

3.6

45.9

%

53.2

6.7

%

compared to

3.6

45.9%

53.2

6.7%

Patients with Complex/Advanced PD treated with non-oral therapies had fewer emergency hospital admissions and hip fractures compared to those on other treatment7*†‡

HES data for Complex/Advanced PD patients7

Stay connected

References

Lökk J, et al. 20127

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome

Peer-reviewed opinions support earlier introduction of non-oral therapies in patients with Complex/Advanced Parkinson’s disease³

When left too late, non-oral therapies may no longer be an appropriate treatment option for patients with PD³

Hospital Episode Statistics (HES) data (2013–2018)^7*

^%

^%

45.9^%

6.7^%

Patients with Complex/Advanced PD treated with non-oral therapies had fewer emergency hospital admissions and hip fractures compared to those on other treatment^7*†‡

HES data for Complex/Advanced PD patients⁷

Lökk J, et al. 2012⁷